AstraZeneca Pipeline & Clinical Trials

Downside risk: What's the chance we get 0 approvals? (important for portfolio planning)
Upside potential: Could we hit 5+ approvals if things go well?
Confidence width: A narrow range (2-4) means more predictable; wide range (0-6) means higher uncertainty

Baxdrostat Hard-to-control hypertension (add-on therapy) NDA

Jun 15, 2026 20 days Calendar →

Camizestrant HR+/HER2- advanced breast cancer with ESR1 mutation NDA

Jun 15, 2026 20 days Calendar →

Datroway (datopotamab deruxtecan) First-line metastatic triple-negative breast cancer (TNBC) sBLA

Jun 30, 2026 35 days Calendar →

Enhertu (trastuzumab deruxtecan) - post-neoadjuvant HER2-positive early breast cancer with residual invasive disease (DESTINY-Breast05) sBLA

Jul 7, 2026 42 days Calendar →

AstraZeneca Pipeline